<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04738487</url>
  </required_header>
  <id_info>
    <org_study_id>7684A-003</org_study_id>
    <secondary_id>MK-7684A-003</secondary_id>
    <secondary_id>2020-004049-35</secondary_id>
    <secondary_id>jRCT2021210025</secondary_id>
    <nct_id>NCT04738487</nct_id>
  </id_info>
  <brief_title>Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003)</brief_title>
  <official_title>A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 With Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary hypotheses are that coformulated pembrolizumab/vibostolimab is superior to&#xD;
      pembrolizumab alone with respect to progression-free survival (PFS) per Response Evaluation&#xD;
      Criteria in Solid Tumors (RECIST) 1.1 by blinded independent central review (BICR), and with&#xD;
      respect to overall survival (OS), in participants with non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 7, 2021</start_date>
  <completion_date type="Anticipated">April 29, 2027</completion_date>
  <primary_completion_date type="Anticipated">April 4, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Up to approximately 38 months</time_frame>
    <description>PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review will be presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 46 months</time_frame>
    <description>OS is defined as the time from randomization to death due to any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. The percentage of participants who experience a CR or PR as assessed by blinded independent central review based on RECIST 1.1 will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to approximately 46 months</time_frame>
    <description>For participants who demonstrate a Complete Response (CR: Disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. The DOR as assessed by blinded independent central review will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Global Health Status/Quality of Life (Items 29 and 30) Combined Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)</measure>
    <time_frame>Baseline and up to approximately 107 weeks</time_frame>
    <description>Change from baseline in the score of EORTC QLQ-C30 Items 29 and 30 will be presented. The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to Items 29 and 30 (&quot;How would you rate your overall health during the past week?&quot; and &quot;How would you rate your overall quality of life during the past week?&quot;) are scored on a 7-point scale (1=Very Poor to 7=Excellent). A higher score indicates a better overall outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Physical Functioning (Items 1-5) Combined Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)</measure>
    <time_frame>Baseline and up to approximately 107 weeks</time_frame>
    <description>Change from baseline in the score of EORTC QLQ-C30 Items 1-5 will be presented. The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Higher scores indicate a worse level of function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Dyspnea Score (Item 8) on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)</measure>
    <time_frame>Baseline and up to approximately 107 weeks</time_frame>
    <description>Change from baseline in the score of EORTC QLQ-C30 Item 8 will be presented. The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant response to the question &quot;Were you short of breath?&quot; is scored on a 4-point scale (1=Not at All to 4=Very Much). A higher score indicates a worse level of dyspnea.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Cough Score (Item 31) on the European Organization for Research and Treatment of Cancer Quality of Life Lung Cancer-Specific Questionnaire Module (EORTC QLQ-LC13)</measure>
    <time_frame>Baseline and up to approximately 107 weeks</time_frame>
    <description>Change from baseline in the score of EORTC QLQ-C13 Item 31 will be presented. The EORTC QLQ-C13 is a lung cancer specific health-related quality-of life (QoL) questionnaire. Participant response to the question &quot;Have you coughed?&quot; is scored on a 4-point scale (1=Not at All to 4=Very Much). A higher score indicates more frequent coughing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Chest Pain Score (Item 40) on the European Organization for Research and Treatment of Cancer Quality of Life Lung Cancer-Specific Questionnaire Module (EORTC QLQ-LC13)</measure>
    <time_frame>Baseline and up to approximately 107 weeks</time_frame>
    <description>Change from baseline in the score of EORTC QLQ-C13 Item 40 will be presented. The EORTC QLQ-C13 is a lung cancer specific health-related quality-of life (QoL) questionnaire. Participant response to the question &quot;Have you had pain in your chest?&quot; is scored on a 4-point scale (1=Not at All to 4=Very Much). A higher score indicates a worse level of chest pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Deterioration (TTD) in the Global Health Status/Quality of Life (Items 29 and 30) Combined Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)</measure>
    <time_frame>Baseline and up to approximately 107 weeks</time_frame>
    <description>TTD in the score of EORTC QLQ-C30 Items 29 and 30 will be presented. The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to Items 29 and 30 (&quot;How would you rate your overall health during the past week?&quot; and &quot;How would you rate your overall quality of life during the past week?&quot;) are scored on a 7-point scale (1=Very Poor to 7=Excellent). A higher score indicates a better overall outcome. TTD is defined as the time to first onset of 10 or more (out of 100) deterioration from baseline and confirmed by a second adjacent 10 or more deterioration from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTD in Physical Functioning (Items 1-5) Combined Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)</measure>
    <time_frame>Baseline and up to approximately 107 weeks</time_frame>
    <description>TTD in the score of EORTC QLQ-C30 Items 1-5 will be presented. The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Higher scores indicate a worse level of function. TTD is defined as the time to first onset of 10 or more (out of 100) deterioration from baseline and confirmed by a second adjacent 10 or more deterioration from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTD in Dyspnea Score (Item 8) on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)</measure>
    <time_frame>Baseline and up to approximately 107 weeks</time_frame>
    <description>TTD in the score of EORTC QLQ-C30 Item 8 will be presented. The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant response to the question &quot;Were you short of breath?&quot; is scored on a 4-point scale (1=Not at All to 4=Very Much). A higher score indicates a worse level of dyspnea. TTD is defined as the time to first onset of 10 or more (out of 100) deterioration from baseline and confirmed by a second adjacent 10 or more deterioration from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTD in Cough Score (Item 31) on the European Organization for Research and Treatment of Cancer Quality of Life Lung Cancer-Specific Questionnaire Module (EORTC QLQ-LC13)</measure>
    <time_frame>Baseline and up to approximately 107 weeks</time_frame>
    <description>TTD in the score of EORTC QLQ-C13 Item 31 will be presented. The EORTC QLQ-C13 is a lung cancer specific health-related quality-of life (QoL) questionnaire. Participant response to the question &quot;Have you coughed?&quot; is scored on a 4-point scale (1=Not at All to 4=Very Much). A higher score indicates more frequent coughing. TTD is defined as the time to first onset of 10 or more (out of 100) deterioration from baseline and confirmed by a second adjacent 10 or more deterioration from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTD in Chest Pain Score (Item 40) on the European Organization for Research and Treatment of Cancer Quality of Life Lung Cancer-Specific Questionnaire Module (EORTC QLQ-LC13)</measure>
    <time_frame>Baseline and up to approximately 107 weeks</time_frame>
    <description>TTD in the score of EORTC QLQ-C13 Item 40 will be presented. The EORTC QLQ-C13 is a lung cancer specific health-related quality-of life (QoL) questionnaire. Participant response to the question &quot;Have you had pain in your chest?&quot; is scored on a 4-point scale (1=Not at All to 4=Very Much). A higher score indicates a worse level of chest pain. TTD is defined as the time to first onset of 10 or more (out of 100) deterioration from baseline and confirmed by a second adjacent 10 or more deterioration from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced One or More Adverse Events (AEs)</measure>
    <time_frame>Up to approximately 115 weeks</time_frame>
    <description>The number of participants who experienced an adverse event (AE) will be presented. An AE is defined as any untoward medical occurrence in a participant administered study treatment and which did not necessarily have to have a causal relationship with this treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Discontinued Study Intervention Due to an Adverse Event (AE)</measure>
    <time_frame>Up to approximately 103 weeks</time_frame>
    <description>The number of participants who discontinue study intervention due to an adverse event (AE) will be presented. An AE is defined as any untoward medical occurrence in a participant administered study treatment and which did not necessarily have to have a causal relationship with this treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">598</enrollment>
  <condition>Lung Neoplasms</condition>
  <condition>Non-Small-Cell Lung Carcinoma</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab/Vibostolimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive pembrolizumab/vibostolimab as a coformulation (MK-7684A).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive pembrolizumab (MK-3475) alone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab/Vibostolimab</intervention_name>
    <description>Coformulation of pembrolizumab (MK-3475) 200mg and vibostolimab (MK-7684) 200mg. Participants receive the coformulation by intravenous (IV) infusion every 3 weeks (Q3W) for up to 35 administrations.</description>
    <arm_group_label>Pembrolizumab/Vibostolimab</arm_group_label>
    <other_name>MK-7684A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Participants receive 200 mg of pembrolizumab by intravenous (IV) infusion every 3 weeks (Q3W) for up to 35 administrations.</description>
    <arm_group_label>Pembrolizumab</arm_group_label>
    <other_name>MK-3475</other_name>
    <other_name>Keytruda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has a histologically or cytologically confirmed diagnosis of Stage IV: M1a, M1b, or&#xD;
             M1c non-small cell lung cancer (NSCLC) per the American Joint Committee on Cancer&#xD;
             (AJCC) Staging Manual, version 8&#xD;
&#xD;
          -  Has measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST)&#xD;
             1.1, as determined by the local site assessment&#xD;
&#xD;
          -  Has confirmation that epidermal growth factor receptor (EGFR)-, anaplastic lymphoma&#xD;
             kinase (ALK)-, or reactive oxygen species proto-oncogene 1 (ROS1)-directed therapy is&#xD;
             not indicated as primary therapy and absence of ALK and ROS1 gene rearrangements&#xD;
&#xD;
          -  Has provided tumor tissue that demonstrates Programmed Cell Death 1 Ligand 1 (PD-L1)&#xD;
             expression in ≥1% of tumor cells as assessed by immunohistochemistry (IHC) at a&#xD;
             central laboratory&#xD;
&#xD;
          -  Has an Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1 assessed&#xD;
             within 7 days prior to randomization&#xD;
&#xD;
          -  Has a life expectancy of at least 3 months&#xD;
&#xD;
          -  A female participant is eligible to participate if she is not pregnant or&#xD;
             breastfeeding, and at least one of the following conditions applies:&#xD;
&#xD;
               -  Is not a woman of childbearing potential (WOCBP)&#xD;
&#xD;
               -  Is a WOCBP and using a contraceptive method that is highly effective (with a&#xD;
                  failure rate of &lt;1% per year), with low user dependency or be abstinent from&#xD;
                  heterosexual intercourse as their preferred and usual lifestyle (abstinent on a&#xD;
                  long term and persistent basis), during the intervention period and for at least&#xD;
                  120 days after the last dose of study intervention&#xD;
&#xD;
          -  Has adequate organ function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a known history of an additional malignancy, except if the participant has&#xD;
             undergone potentially curative therapy with no evidence of that disease recurrence for&#xD;
             at least 3 years since initiation of that therapy&#xD;
&#xD;
          -  Has received prior systemic chemotherapy or other targeted or biological&#xD;
             antineoplastic therapy for their metastatic NSCLC.&#xD;
&#xD;
               -  Prior treatment with chemotherapy and/or radiation as part of&#xD;
                  neoadjuvant/adjuvant or chemoradiation therapy for nonmetastatic NSCLC is allowed&#xD;
                  as long as therapy was completed at least 6 months before the diagnosis of&#xD;
                  metastatic NSCLC.&#xD;
&#xD;
               -  Participants must have recovered from all AEs due to previous therapies to Grade&#xD;
                  ≤1 or baseline. Participants with Grade ≤2 neuropathy may be eligible.&#xD;
                  Participants with endocrine-related AEs Grade ≤2 requiring treatment or hormone&#xD;
                  replacement may be eligible.&#xD;
&#xD;
          -  Has received prior therapy with an anti-programmed cell death receptor 1 (PD-1),&#xD;
             anti-programmed cell death receptor ligand 1 (PD-L1), or anti-programmed cell death&#xD;
             receptor ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or&#xD;
             co-inhibitory T-cell receptor (eg, cytotoxic T-lymphocyte-associated protein 4&#xD;
             (CTLA-4), OX-40, CD137)&#xD;
&#xD;
          -  Has received previous treatment with another agent targeting the T cell immunoreceptor&#xD;
             with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibition motif (ITIM)&#xD;
             domains (TIGIT) receptor pathway&#xD;
&#xD;
          -  Has received radiotherapy within 2 weeks of start of study intervention. Participants&#xD;
             must have recovered from all radiation-related toxicities, not require&#xD;
             corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted&#xD;
             for palliative radiation (≤2 weeks of radiotherapy) to non-central nervous system&#xD;
             (CNS) disease&#xD;
&#xD;
          -  Has received a live or live-attenuated vaccine within 30 days prior to the first dose&#xD;
             of study intervention. Administration of killed vaccines is allowed&#xD;
&#xD;
          -  Is currently participating in or has participated in a study of an investigational&#xD;
             agent or has used an investigational device within 4 weeks prior to the first dose of&#xD;
             study intervention&#xD;
&#xD;
          -  Has known active or untreated CNS metastases and/or carcinomatous meningitis.&#xD;
             Participants with previously treated brain metastases may participate provided they&#xD;
             are radiologically stable for at least 4 weeks by repeat imaging, clinically stable,&#xD;
             and without requirement of steroid treatment for at least 14 days prior to first dose&#xD;
             of study intervention&#xD;
&#xD;
          -  Has severe hypersensitivity (≥Grade 3) to pembrolizumab/vibostolimab or pembrolizumab&#xD;
             and/or any of its excipients&#xD;
&#xD;
          -  Has an active autoimmune disease that has required systemic treatment in past 2 years&#xD;
             (ie, with use of disease modifying agents, corticosteroids, or immunosuppressive&#xD;
             drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid&#xD;
             replacement therapy for adrenal or pituitary insufficiency) is not considered a form&#xD;
             of systemic treatment and is allowed.&#xD;
&#xD;
          -  Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy&#xD;
             (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of&#xD;
             immunosuppressive therapy within 7 days prior to the first dose of study intervention&#xD;
&#xD;
          -  Has a history of (non-infectious) pneumonitis that required steroids or has current&#xD;
             pneumonitis&#xD;
&#xD;
          -  Has a known history of interstitial lung disease. Lymphangitic spread of the NSCLC is&#xD;
             not exclusionary.&#xD;
&#xD;
          -  Has an active infection requiring systemic therapy&#xD;
&#xD;
          -  Has a known history of human immunodeficiency virus (HIV) infection. No HIV testing is&#xD;
             required unless mandated by local health authority&#xD;
&#xD;
          -  Has a known history of Hepatitis B or known active Hepatitis C virus infection&#xD;
&#xD;
          -  Has a known psychiatric or substance abuse disorder that would interfere with the&#xD;
             participant's ability to cooperate with the requirements of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Boca Raton Regional Hospital ( Site 0004)</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>561-955-4862</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Illinois Cancer Care ( Site 0026)</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>000-000-0000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mercy Research - David C. Pratt Cancer Center ( Site 0025)</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>000-000-0000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mercy Research - Cancer and Hematology Center ( Site 0032)</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>000-000-0000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>BC Cancer Victoria-Clinical Trials Unit ( Site 0107)</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 6V5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>2505195572</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>James Lind Centro de Investigación del Cáncer ( Site 0711)</name>
      <address>
        <city>Temuco</city>
        <state>Araucania</state>
        <zip>4780000</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56452982404</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CIDO SpA-Oncology ( Site 0707)</name>
      <address>
        <city>Temuco</city>
        <state>Araucania</state>
        <zip>4810148</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>569 5 798 31 73</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>IC La Serena Research ( Site 0710)</name>
      <address>
        <city>La Serena</city>
        <state>Coquimbo</state>
        <zip>1720430</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56512386127</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad Catolica del Maule-Oncology ( Site 0703)</name>
      <address>
        <city>Talca</city>
        <state>Maule</state>
        <zip>3465584</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56712635600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>FALP ( Site 0702)</name>
      <address>
        <city>Providencia</city>
        <state>Region M. De Santiago</state>
        <zip>7500912</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56227067543</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Intervasc ( Site 0306)</name>
      <address>
        <city>Guatemala City</city>
        <zip>01010</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+50259042511</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CELAN,S.A ( Site 0304)</name>
      <address>
        <city>Guatemala</city>
        <zip>01010</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+50242142081</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gastrosoluciones ( Site 0302)</name>
      <address>
        <city>Guatemala</city>
        <zip>01010</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+50245711895</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>INTEGRA Cancer Institute ( Site 0303)</name>
      <address>
        <city>Guatemala</city>
        <zip>01010</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+502 54530410</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncomedica-Guatemala ( Site 0301)</name>
      <address>
        <city>Guatemala</city>
        <zip>01010</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+50256973689</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hong Kong Integrated Oncology Centre ( Site 1301)</name>
      <address>
        <city>Central</city>
        <zip>00000</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+85237006888</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital ( Site 1303)</name>
      <address>
        <city>Hksar</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+85222554361</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hong Kong United Oncology Centre ( Site 1302)</name>
      <address>
        <city>Kowloon</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+85223868002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bacs-Kiskun Megyei Korhaz-Onkoradiologiai Kozpont ( Site 1201)</name>
      <address>
        <city>Kecskemét</city>
        <state>Bacs-Kiskun</state>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3676519853</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Petz Aladar Egyetemi Oktato Korhaz-Pulmonológia ( Site 1205)</name>
      <address>
        <city>Gyor</city>
        <state>Gyor-Moson-Sopron</state>
        <zip>9024</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3696507900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház-Onkologiai Kozpont ( Site 1200)</name>
      <address>
        <city>Szolnok</city>
        <state>Jasz-Nagykun-Szolnok</state>
        <zip>5004</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3656503603</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Torokbalint Tudogyogyintezet-Onkopulmonologiai Jarobeteg Centrum ( Site 1208)</name>
      <address>
        <city>Törökbálint</city>
        <state>Pest</state>
        <zip>2045</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36307005601</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Semmelweis University-Pulmonológiai Klinika ( Site 1209)</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3614591500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fujita Health University ( Site 1906)</name>
      <address>
        <city>Toyoake</city>
        <state>Aichi</state>
        <zip>470-1192</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-562-93-2111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ehime University Hospital ( Site 1911)</name>
      <address>
        <city>Toon</city>
        <state>Ehime</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-89-964-5111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kanagawa cancer center ( Site 1916)</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>2418515</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-45-520-2222</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sendai Kousei Hospital ( Site 1900)</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>9800873</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-22-222-6181</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kansai Medical University Hospital ( Site 1914)</name>
      <address>
        <city>Hirakata</city>
        <state>Osaka</state>
        <zip>5721191</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-72-804-0101</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kindai University Hospital- Osakasayama Campus ( Site 1907)</name>
      <address>
        <city>Osaka-sayama</city>
        <state>Osaka</state>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-72-366-0221</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka Medical and Pharmaceutical University Hospital ( Site 1908)</name>
      <address>
        <city>Takatsuki</city>
        <state>Osaka</state>
        <zip>569-8686</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-72-683-1221</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shizuoka Cancer Center ( Site 1905)</name>
      <address>
        <city>Nagaizumi</city>
        <state>Shizuoka</state>
        <zip>411-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-55-989-5222</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital ( Site 1913)</name>
      <address>
        <city>Okayama</city>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-86-223-7151</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka International Cancer Institute ( Site 1915)</name>
      <address>
        <city>Osaka</city>
        <zip>541-8567</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81669451181</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Juntendo University Hospital ( Site 1902)</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8431</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-3-3813-3111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Japanese Foundation for Cancer Research ( Site 1901)</name>
      <address>
        <city>Tokyo</city>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-3-3520-0111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wakayama Medical University Hospital ( Site 1910)</name>
      <address>
        <city>Wakayama</city>
        <zip>641-0012</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-73-447-2300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chungbuk National University Hospital-Internal medicine ( Site 1406)</name>
      <address>
        <city>Cheongju-si</city>
        <state>Chungbuk</state>
        <zip>28644</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82-42-269-8760</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital ( Site 1403)</name>
      <address>
        <city>Seongnam</city>
        <state>Kyonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82-31-1588-3369</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Catholic University Of Korea St. Vincent's Hospital-Medical Oncology ( Site 1405)</name>
      <address>
        <city>Suwon-si</city>
        <state>Kyonggi-do</state>
        <zip>16247</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82-31-1577-8588</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital ( Site 1401)</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82-2-2072-2995</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System ( Site 1402)</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82-2-1599-1004</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center ( Site 1400)</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82-2-3010-3214</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Pulau Pinang ( Site 1501)</name>
      <address>
        <city>George Town</city>
        <state>Pulau Pinang</state>
        <zip>10990</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>6042225768</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute ( Site 1505)</name>
      <address>
        <city>Putrajaya</city>
        <state>Wilayah Persekutuan Putrajaya</state>
        <zip>62250</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>60388925555</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moscow Regional Oncological Dispensary ( Site 0812)</name>
      <address>
        <city>Balashikha</city>
        <state>Moskovskaya Oblast</state>
        <zip>143900</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+74955212231</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical-Oncology department ( Site 0814)</name>
      <address>
        <city>Moscow</city>
        <state>Moskovskaya Oblast</state>
        <zip>121205</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79150211451</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Clinical Hospital of the Presidential Administrative Department ( Site 0802)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>121359</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+74955300111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nizhegorodsky Regional Oncology Dispensary, Branch #2-chemotherapy ( Site 0809)</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <state>Nizhegorodskaya Oblast</state>
        <zip>603081</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79107959868</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>GBUZ LOKB-Oncology department #1 ( Site 0804)</name>
      <address>
        <city>Saint-Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79219075211</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Republican Clinical Oncology Dispensary ( Site 0805)</name>
      <address>
        <city>Kazan</city>
        <state>Tatarstan, Respublika</state>
        <zip>420029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79172662851</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Scientific research institution of oncology named after N.N. Petrov-Thoracic oncology ( Site 0803)</name>
      <address>
        <city>Sankt-Peterburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79117500005</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sandton Oncology Medical Group (Pty) Ltd-Research ( Site 0902)</name>
      <address>
        <city>Sandton</city>
        <state>Gauteng</state>
        <zip>2196</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>27118830900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Oncology Centre ( Site 0905)</name>
      <address>
        <city>Durban</city>
        <state>Kwazulu-Natal</state>
        <zip>4091</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27312088666</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital at Kaohsiung ( Site 1702)</name>
      <address>
        <city>Kaohsiung Niao Sung Dist</city>
        <state>Kaohsiung</state>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+88677317123</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital - Hsinchu branch ( Site 1704)</name>
      <address>
        <city>Hsinchu</city>
        <zip>300</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886353261514529</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>NATIONAL CHENG-KUNG UNI. HOSP.-clinical trial center ( Site 1705)</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886623535354559</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital-Chest Medicine ( Site 1703)</name>
      <address>
        <city>Taipei</city>
        <zip>10449</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886-25433535</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erciyes University Medical Oncology Department ( Site 1007)</name>
      <address>
        <city>Talas</city>
        <state>Kayseri</state>
        <zip>38039</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+903524374912</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hacettepe Universitesi-oncology hospital ( Site 1001)</name>
      <address>
        <city>Ankara</city>
        <zip>06230</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+903123052929</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Ankara Hastanesi-Medical Oncology ( Site 1002)</name>
      <address>
        <city>Ankara</city>
        <zip>06520</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+903122536666</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gazi Universitesi-Oncology ( Site 1003)</name>
      <address>
        <city>Ankara</city>
        <zip>06560</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+903122025825</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Acıbadem Maslak Hastanesi ( Site 1008)</name>
      <address>
        <city>İstanbul</city>
        <zip>34457</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>905062979770</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istanbul Universitesi Cerrahpasa-Medical Oncology ( Site 1000)</name>
      <address>
        <city>Istanbul</city>
        <zip>34668</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905324167355</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsun Medical Park Hastanesi-medical oncology ( Site 1005)</name>
      <address>
        <city>Samsun</city>
        <zip>55200</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0903623114040</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cherkasy Regional Oncology Dispensary ( Site 1110)</name>
      <address>
        <city>Cherkassy</city>
        <state>Cherkaska Oblast</state>
        <zip>18009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380501606360</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chernihiv Medical Center of Modern Oncology-Clinical oncology and gynecology department ( Site 1113)</name>
      <address>
        <city>Chernihiv</city>
        <state>Chernihivska Oblast</state>
        <zip>14029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380507058899</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Municipal Non-profit Enterprise City Clinical Hospital #4 of Dnipro City Council ( Site 1100)</name>
      <address>
        <city>Dnipro</city>
        <state>Dnipropetrovska Oblast</state>
        <zip>49102</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380675625054</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MI Kryvyi Rih Oncology Dispensary of Dnipropetrovsk Regional-Chemotherapy department ( Site 1104)</name>
      <address>
        <city>Kryvyi Rih</city>
        <state>Dnipropetrovska Oblast</state>
        <zip>50048</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380564723341</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Communal Non-Commercial Enterprise Prykarpatski Clinical Oncological Center of Ivano-Frankivsk Regio</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <state>Ivano-Frankivska Oblast</state>
        <zip>76018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380978411455</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of General and Emergency Surgery named after V.T. Zaitsev NAMS of Ukraine ( Site 1119)</name>
      <address>
        <city>Kharkiv</city>
        <state>Kharkivska Oblast</state>
        <zip>61103</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380503233704</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute ( Site 1114)</name>
      <address>
        <city>Kyiv</city>
        <state>Kyivska Oblast</state>
        <zip>03022</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380509095151</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vinnytsia Regional Clinical Oncological Hospital ( Site 1102)</name>
      <address>
        <city>Vinnytsia</city>
        <state>Vinnytska Oblast</state>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380975791841</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uzhgorod Central City Clinical Hospital-City oncology center ( Site 1120)</name>
      <address>
        <city>Uzhhorod</city>
        <state>Zakarpatska Oblast</state>
        <zip>88000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380505048997</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncolife LLC-day-stay department ( Site 1107)</name>
      <address>
        <city>Zaporizhzhia</city>
        <state>Zaporizka Oblast</state>
        <zip>69059</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380973153178</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhytomyr Regional Oncology Center-Chemotherapy Department ( Site 1103)</name>
      <address>
        <city>Zhytomyr</city>
        <state>Zhytomyrska Oblast</state>
        <zip>10002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380412430391</phone>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Chile</country>
    <country>Guatemala</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 2, 2021</study_first_submitted>
  <study_first_submitted_qc>February 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Programmed Cell Death-1 (PD1, PD-1)</keyword>
  <keyword>Programmed Cell Death 1 Ligand 1 (PDL1, PD-L1)</keyword>
  <keyword>Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

